CA2143187C - Vaccins anti-virus d'immunodeficience chez les felins - Google Patents

Vaccins anti-virus d'immunodeficience chez les felins Download PDF

Info

Publication number: CA2143187C
Authority: CA; Canada
Prior art keywords: seq; immunodeficiency virus; sequence; feline immunodeficiency; fiv
Prior art date: 1992-09-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002143187A

Other languages

English (en)

Other versions

CA2143187A1 (fr

Inventor

Michael James Francis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mallinckrodt Veterinary Inc

Original Assignee

Mallinckrodt Veterinary Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-21

Filing date

1993-09-20

Publication date

2007-05-22

1992-09-21 Priority claimed from GB929219936A external-priority patent/GB9219936D0/en

1993-09-20 Application filed by Mallinckrodt Veterinary Inc filed Critical Mallinckrodt Veterinary Inc

1994-03-31 Publication of CA2143187A1 publication Critical patent/CA2143187A1/fr

2007-05-22 Application granted granted Critical

2007-05-22 Publication of CA2143187C publication Critical patent/CA2143187C/fr

2013-09-20 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title abstract description 39
241000700605 Viruses Species 0.000 title description 24
206010061598 Immunodeficiency Diseases 0.000 title description 2
208000029462 Immunodeficiency disease Diseases 0.000 title description 2
230000007813 immunodeficiency Effects 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 187
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 155
229920001184 polypeptide Polymers 0.000 claims abstract description 99
238000000034 method Methods 0.000 claims abstract description 27
239000000203 mixture Substances 0.000 claims abstract description 26
150000007523 nucleic acids Chemical class 0.000 claims abstract description 25
108020004707 nucleic acids Proteins 0.000 claims abstract description 24
102000039446 nucleic acids Human genes 0.000 claims abstract description 24
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
230000000890 antigenic effect Effects 0.000 claims abstract description 15
238000002360 preparation method Methods 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 10
239000012634 fragment Substances 0.000 claims abstract description 9
241000713800 Feline immunodeficiency virus Species 0.000 claims description 131
125000003729 nucleotide group Chemical group 0.000 claims description 21
239000002773 nucleotide Substances 0.000 claims description 20
241001465754 Metazoa Species 0.000 claims description 18
108090000623 proteins and genes Proteins 0.000 claims description 17
102000004169 proteins and genes Human genes 0.000 claims description 17
230000028993 immune response Effects 0.000 claims description 12
230000002163 immunogen Effects 0.000 claims description 11
239000013604 expression vector Substances 0.000 claims description 9
108700004025 env Genes Proteins 0.000 claims description 8
101150030339 env gene Proteins 0.000 claims description 8
230000003472 neutralizing effect Effects 0.000 claims description 8
102000037865 fusion proteins Human genes 0.000 claims description 6
108020001507 fusion proteins Proteins 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
102000014914 Carrier Proteins Human genes 0.000 claims description 3
108010078791 Carrier Proteins Proteins 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 3
230000009918 complex formation Effects 0.000 claims description 3
238000010511 deprotection reaction Methods 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 2
230000000638 stimulation Effects 0.000 claims description 2
238000011282 treatment Methods 0.000 claims description 2
101900225097 Feline immunodeficiency virus Envelope glycoprotein gp150 Proteins 0.000 claims 4
239000013599 cloning vector Substances 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 15
241000282326 Felis catus Species 0.000 description 53
235000018102 proteins Nutrition 0.000 description 16
101710091045 Envelope protein Proteins 0.000 description 15
102100034349 Integrase Human genes 0.000 description 15
101710188315 Protein X Proteins 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
210000004027 cell Anatomy 0.000 description 13
238000002965 ELISA Methods 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
-1 amino acid esters Chemical class 0.000 description 9
238000005859 coupling reaction Methods 0.000 description 9
230000004044 response Effects 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
230000002788 anti-peptide Effects 0.000 description 8
210000004899 c-terminal region Anatomy 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
230000004936 stimulating effect Effects 0.000 description 8
238000007792 addition Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
101710132601 Capsid protein Proteins 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
230000036039 immunity Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000001262 western blot Methods 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
241000700618 Vaccinia virus Species 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000013598 vector Substances 0.000 description 5
241000700198 Cavia Species 0.000 description 4
241000282324 Felis Species 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
230000005875 antibody response Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
208000006454 hepatitis Diseases 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
125000006242 amine protecting group Chemical group 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
229940023041 peptide vaccine Drugs 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000000047 product Substances 0.000 description 3
241000712461 unidentified influenza virus Species 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000710198 Foot-and-mouth disease virus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102100034353 Integrase Human genes 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
101710176384 Peptide 1 Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
108010078428 env Gene Products Proteins 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
229940031348 multivalent vaccine Drugs 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
238000002708 random mutagenesis Methods 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000702673 Bovine rotavirus Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000709691 Enterovirus E Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000002613 Feline Panleukopenia Diseases 0.000 description 1
241000714201 Feline calicivirus Species 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000251188 Holocephali Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000617996 Human rotavirus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010051497 Rhinotracheitis Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
150000001944 cysteine derivatives Chemical class 0.000 description 1
150000001945 cysteines Chemical group 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
208000021601 lentivirus infection Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007119 pathological manifestation Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
108020001775 protein parts Proteins 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940126577 synthetic vaccine Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002143187A 1992-09-21 1993-09-20 Vaccins anti-virus d'immunodeficience chez les felins Expired - Fee Related CA2143187C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB929219936A GB9219936D0 (en)	1992-09-21	1992-09-21	Vaccines
GB9219936.3		1992-09-21
PCT/GB1993/001974 WO1994006471A1 (fr)	1992-09-21	1993-09-20	Vaccins destines a lutter contre le virus immunodeficitaire felin

Publications (2)

Publication Number	Publication Date
CA2143187A1 CA2143187A1 (fr)	1994-03-31
CA2143187C true CA2143187C (fr)	2007-05-22

Family

ID=38151927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002143187A Expired - Fee Related CA2143187C (fr)	1992-09-21	1993-09-20	Vaccins anti-virus d'immunodeficience chez les felins

Country Status (1)

Country	Link
CA (1)	CA2143187C (fr)

1993
- 1993-09-20 CA CA002143187A patent/CA2143187C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2143187A1 (fr)	1994-03-31

Publication	Publication Date	Title
EP0661999B1 (fr)	1998-12-30	Vaccins destines a lutter contre le virus immunodeficitaire felin
McLAIN et al.	1995	Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus
Lombardi et al.	1993	Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope
EP0328403A2 (fr)	1989-08-16	Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
EP1149115A1 (fr)	2001-10-31	TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1
KR101121754B1 (ko)	2012-03-23	Ｅ형 간염 바이러스의 폴리펩티드 단편, 그를 이용한 백신 조성물 및 진단용 키트
EP1098910A1 (fr)	2001-05-16	Complexe antigenique comprenant un peptide immunostimulateur, cd4 et un domaine de recepteur de chemokine pour traiter vih et des maladies immunitaires
AU7569294A (en)	1995-03-21	Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
JPH05262667A (ja)	1993-10-12	ウイルス抗原を用いるワクチン
EP1383795B1 (fr)	2007-01-24	Mutant de nucleoproteine du virus de la maladie de newcastle (vmn) de recombinaison tenant lieu de vaccin marqueur
US20020018780A1 (en)	2002-02-14	Epitope-based vaccine for respiratory syncytial virus F-protein
JP2009005706A (ja)	2009-01-15	抗−ネコ免疫不全ウイルス（ｆｉｖ）ワクチン
AU631894B2 (en)	1992-12-10	Conjugate immunogen for aids
CA1271717A (fr)	1990-07-17	Polypeptides utiles dans la vaccination contre les enterovirus
Boudet et al.	1992	Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120
CN111454989A (zh)	2020-07-28	一种嵌合型基因i型乙型脑炎病毒病毒样颗粒疫苗及其制备方法和应用
CA2143187C (fr)	2007-05-22	Vaccins anti-virus d'immunodeficience chez les felins
KR101937792B1 (ko)	2019-01-14	신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
DK2571519T3 (en)	2016-10-17	Marker vaccine against classical swine fever
WO1994002613A1 (fr)	1994-02-03	Vaccins contre le virus de l'immunodeficience anti-feline (vif)
DE69433057T2 (de)	2004-06-03	Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
EP0448095A1 (fr)	1991-09-25	Sous-région de la protéine ENV rétrovirale, séquences d'ADN codant pour celle-ci et compositions pour le diagnostic, la prévention ou la thérapie des infections rétrovirales
Cranage et al.	1995	The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine
CN111803626A (zh)	2020-10-23	猪口蹄疫o型和a型二价合成肽疫苗及其制备方法与应用
WO2009053512A1 (fr)	2009-04-30	Protéines n, m, he du torovirus porcin, procédé d'obtention et leurs utilisations dans le diagnostic et le traitement de torovirus porcin

Legal Events

Date	Code	Title	Description
2000-09-15	EEER	Examination request
2011-09-20	MKLA	Lapsed